India's First Open-Source, Evidence-Based GLP-1 Weight Loss Telehealth Platform
India has 135 million obese individuals — the fastest-growing obesity epidemic in the world. According to NFHS-5 (2019-21), 44% of urban men and 52% of urban women are overweight or obese. India now ranks #2 globally in childhood obesity after China.
Yet, there is no standardized, doctor-supervised, affordable digital platform for evidence-based weight loss in India — until now.
India Fat to Fit is an open-source telehealth platform that connects patients with licensed physicians for Semaglutide-based weight loss therapy, backed by the largest clinical trial program in obesity history — the STEP trials.
| Trial | Weight Loss | vs Placebo | Duration | Journal | DOI |
|---|---|---|---|---|---|
| STEP 1 | -14.9% | -2.4% | 68 weeks | JAMA | 10.4103/2230-8210.342310 |
| STEP 2 | -9.6% | -3.4% | 68 weeks | JAMA | 10.4103/2230-8210.342311 |
| STEP 3 | -16.0% | -5.7% | 68 weeks | JAMA | 10.1001/jama.2021.1831 |
| STEP 4 | -17.4% | +6.9%* | 68 weeks | JAMA | 10.1001/jama.2021.3224 |
| STEP 5 | -15.2% | -2.6% | 104 weeks | Nature Medicine | 10.1038/s41591-022-02026-4 |
| STEP 8 | -15.8% | -6.4%† | 68 weeks | JAMA | 10.1001/jama.2021.23619 |
*STEP 4: Withdrawal design — placebo group regained +6.9% after stopping semaglutide †STEP 8: Comparator was liraglutide 3mg (not placebo)
The SELECT trial demonstrated that semaglutide reduces major adverse cardiovascular events (MACE) by 20% and stroke risk by 35%, independent of glycemic status (European Heart Journal, 2024).
Every chart links directly to its PubMed/PMC source:
- STEP Trials Weight Loss — Grouped bar chart comparing semaglutide vs placebo across all 6 major trials
- GLP-1 Drug Comparison — Semaglutide vs Tirzepatide vs Liraglutide vs Orlistat (JAMA Internal Medicine)
- India Obesity by Region — Zone-wise prevalence data from NMB-2017 / PMC8455012
- NFHS-4 vs NFHS-5 Trends — Rising obesity rates 2015-16 to 2019-21 (PMC10611613)
- Top 10 Indian States — State-wise obesity prevalence from NFHS-5
- Cardiovascular Benefits — MACE and stroke reduction from SELECT trial
- Weight Loss Timeline — Projected 68-week weight loss curve based on STEP 1 data
- BMI Classification — WHO vs Indian consensus standards (Indian Heart Journal, PMC5903015)
- 6-Step Health Assessment — Clinically validated questionnaire with auto BMI calculator (Indian classification)
- Razorpay Integration — ₹999 consultation fee, UPI/Cards/NetBanking
- Doctor Review Dashboard — Digital signature and approval workflow
- 4-Tier Pricing — Kickstart (1mo) → Total Reset (12mo) with progressive drug discounts
- Indian Diet Plans — Region-specific (North, South, Bengali, Gujarati) per ICMR-NIN 2024 guidelines
- Evidence Library — Filterable repository of 15+ clinical studies with DOI badges
- Supplement Store — White-label products integrated with treatment plans
- BMI thresholds: Uses Indian consensus guidelines (Overweight ≥23, Obese ≥25) instead of WHO (≥25/≥30)
- Regional cuisine support: Diet plans for North Indian, South Indian, Bengali, Gujarati, Rajasthani, Maharashtrian, Kerala
- ICMR-NIN 2024: "My Plate for the Day" dietary guidelines integrated
- NMC Telemedicine compliant: Adheres to National Medical Commission guidelines
- DPDP Act 2023: Digital Personal Data Protection Act compliance
- Clash Display + Satoshi typography (Fontshare)
- Dark/light mode with CSS custom properties
- Scroll-triggered animations (IntersectionObserver)
- Animated counter stats
- Glassmorphism UI elements
- Mobile-first responsive design
- Structured JSON-LD for SEO
# Clone the repository
git clone https://github.com/akhileshwar994/AKIVA-HEALTH-INDIA-FAT-TO-FIT-PROGRAM.git
# Navigate to project
cd AKIVA-HEALTH-INDIA-FAT-TO-FIT-PROGRAM
# Serve locally (any static server works)
npx serve .
# Or simply open index.html in your browser
open index.htmlNo build tools, no dependencies, no frameworks. Just HTML + CSS + JS.
| Layer | Technology |
|---|---|
| Frontend | Vanilla HTML5, CSS3, JavaScript ES6+ |
| Charts | Chart.js via CDN |
| Icons | Lucide Icons via CDN |
| Fonts | Clash Display + Satoshi via Fontshare CDN |
| Payments | Razorpay Checkout.js |
| Routing | Hash-based SPA routing |
| Hosting | Static deployment (Vercel/Netlify/S3/GitHub Pages) |
├── index.html # Single-page application (1,128 lines)
├── style.css # Complete design system with dark mode (1,911 lines)
├── app.js # Interactive features, charts, forms (868 lines)
├── screenshots/ # Documentation screenshots
│ ├── hero.png
│ ├── crisis.png
│ ├── charts.png
│ ├── pricing.png
│ └── mobile.png
├── CONTRIBUTING.md # Contribution guidelines
├── LICENSE # MIT License
├── CLINICAL_SOURCES.md # Complete citation list
└── README.md # This file
All data visualizations are sourced from peer-reviewed, PubMed-indexed publications:
| Source | Journal | Year | Used For |
|---|---|---|---|
| STEP 1 Trial | Indian J Endocr Metab | 2022 | Weight loss efficacy chart |
| STEP 3 Trial | JAMA | 2021 | Behavioral therapy outcomes |
| STEP 4 Trial | JAMA | 2021 | Weight maintenance data |
| STEP 5 Trial | Nature Medicine | 2022 | 2-year sustained outcomes |
| STEP 8 Trial | JAMA | 2022 | Semaglutide vs Liraglutide |
| SELECT Trial | Diabetes Care / Eur Heart J | 2024 | Cardiovascular outcomes |
| Tirzepatide vs Semaglutide | JAMA Internal Medicine | 2024 | Drug comparison |
| NFHS-5 Analysis | Advances in Therapy | 2023 | India obesity trends |
| India Obesity Prevalence | Annals of Neurosciences | 2021 | Regional/state data |
| Asian Indian BMI Cutoffs | Indian Heart Journal | 2017 | BMI classification |
| ICMR-NIN Guidelines | NIN/ICMR | 2024 | Indian dietary guidelines |
| World Obesity Atlas | World Obesity Federation | 2026 | Childhood obesity ranking |
| GLP-1 Meta-analysis | Frontiers in Pharmacology | 2025 | Drug efficacy comparison |
See CLINICAL_SOURCES.md for complete citation list with DOIs.
Replace the test key in app.js:
// Find this line and replace with your actual Razorpay key_id
key: "rzp_test_DEMO" // → Replace with: "rzp_live_YOUR_KEY_HERE"Access the doctor's review panel at /#admin:
- Default password:
akiva2024(change in production) - Approve/reject patient submissions
- Digital signature workflow
Update in index.html:
// WhatsApp number
wa.me/917801009912
// Email
care@indiafattofit.com# Enable GitHub Pages in Settings → Pages → Source: main branch
# Site will be live at: https://akhileshwar994.github.io/AKIVA-HEALTH-INDIA-FAT-TO-FIT-PROGRAM/npm i -g vercel
vercel --prodDrag and drop the project folder, or connect the GitHub repo.
Add a CNAME record pointing to your hosting provider. All assets load from CDN — zero server dependencies.
| Code | Description |
|---|---|
| E66.01 | Morbid (severe) obesity due to excess calories |
| E66.09 | Other obesity due to excess calories |
| E66.1 | Drug-induced obesity |
| E66.2 | Morbid obesity with alveolar hypoventilation |
| E66.3 | Overweight |
| E66.8 | Other obesity |
| E66.9 | Obesity, unspecified |
| Z68.30-Z68.45 | Body mass index (BMI) 30.0-49.9, adult |
We welcome contributions from developers, designers, clinicians, and public health researchers. See CONTRIBUTING.md for guidelines.
Areas where help is needed:
- Multi-language support (Hindi, Tamil, Telugu, Bengali, Marathi)
- Backend API development (Node.js/Python)
- Electronic Health Records (EHR) integration
- Mobile app (React Native)
- AI-powered diet plan generator
- Integration with Indian health insurance APIs
- WhatsApp Business API chatbot
- Blood work report OCR and analysis
- Wearable device integration (Fitbit, Apple Watch)
- Real patient outcome tracking dashboard
| Regulation | Status |
|---|---|
| NMC Telemedicine Practice Guidelines (2020) | ✅ Compliant |
| DPDP Act 2023 (Digital Personal Data Protection) | ✅ Compliant |
| ICMR-NIN Dietary Guidelines 2024 | ✅ Referenced |
| Indian Consensus BMI Guidelines | ✅ Implemented |
| Razorpay PCI DSS Compliance | ✅ Via Razorpay |
| Strict No-Refund Policy | ✅ Documented |
This project is licensed under the MIT License. Clinical evidence citations are for educational and informational purposes. This platform does not replace professional medical advice.
This platform is designed to facilitate doctor-supervised weight loss treatment. All GLP-1 medications are prescription drugs that must be prescribed by a licensed medical practitioner after proper clinical assessment. The clinical data presented is sourced from peer-reviewed publications and is provided for educational purposes. Individual results may vary.
Built with ❤️ in India by Akiva Health
Dr. Akhileshwar Reddy Vangala, MBBS, MD (Community Medicine)
🌐 Website •
💬 WhatsApp •
📧 Email
If this project helps advance evidence-based weight management in India, please consider giving it a ⭐